Literature DB >> 2521507

Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells.

R Hirsch1, R E Gress, D H Pluznik, M Eckhaus, J A Bluestone.   

Abstract

Anti-CD3 mAb are known to be both immunosuppressive and mitogenic to T cells in vitro. However, only immunosuppression has been observed after in vivo administration of these mAb. The present study demonstrates that T cell activation does occur after in vivo administration of anti-CD3 mAb to mice, evidenced by increased IL-2R expression on T cells, CSF secretion, and extra-medullary hematopoiesis in the spleen. These effects required multivalent cross-linking of the mAb, since F(ab')2 fragments failed to induce them. However, the F(ab')2 fragments did induce modulation of CD3/TCR from the surface of T cells, demonstrating that TCR modulation is not sufficient to induce activation. In addition, interaction of the TCR with either intact or F(ab')2 fragments of the mAb led to increased expression of CD8 in vivo, suggesting that the F(ab')2 fragments of anti-CD3 mAb might be capable of inducing a T cell to undergo some, but not all, of the changes involved in reaching a fully activated state. Further study of the activating effects of anti-CD3 mAb might increase the understanding of the mechanisms of in vivo T cell activation and might also be exploited clinically to stimulate T cell function in immunocompromised states and to enhance hematopoiesis in myelodysplastic disorders.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521507

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Induction of IL-15 by TCR/CD3 aggregation depends on IFN-gamma and protects against apoptosis of immature thymocytes in vivo.

Authors:  P Matthys; H Dooms; P Rottiers; T Mitera; L Overgergh; G Leclercq; A Billiau; J Grooten
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

Review 2.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

3.  Nitric oxide mediates murine cytomegalovirus-associated pneumonitis in lungs that are free of the virus.

Authors:  K Tanaka; H Nakazawa; K Okada; K Umezawa; N Fukuyama; Y Koga
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

4.  Limitations in immunotherapy with CD3 antibodies: comment on the article by Drs. Chatenoud and Bach.

Authors:  Damien Bresson; Matthias von Herrath
Journal:  Rev Diabet Stud       Date:  2006-02-10

5.  Acute inflammation alters bicarbonate transport in mouse ileum.

Authors:  Hui Zhang; Nadia Ameen; James E Melvin; Sadasivan Vidyasagar
Journal:  J Physiol       Date:  2007-03-29       Impact factor: 5.182

6.  Poor induction of interleukin-2 receptor expression on CD8bright+ cells in whole blood cell cultures with CD3 mAb. Implications for immunotherapy with CD3 mAb.

Authors:  R A Janssen; A A Heijn; T H The; L de Leij
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

7.  Intravenous immunoglobulin therapy in multiple sclerosis: progress from remyelination in the Theiler's virus model to a randomised, double-blind, placebo-controlled clinical trial.

Authors:  J H Noseworthy; P C O'Brien; B G van Engelen; M Rodriguez
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-11       Impact factor: 10.154

8.  Anti-tumor necrosis factor modulates anti-CD3-triggered T cell cytokine gene expression in vivo.

Authors:  C Ferran; F Dautry; S Mérite; K Sheehan; R Schreiber; G Grau; J F Bach; L Chatenoud
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

9.  Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.

Authors:  Kevan C Herold; Stephen Gitelman; Carla Greenbaum; Jennifer Puck; William Hagopian; Peter Gottlieb; Peter Sayre; Peter Bianchine; Emelita Wong; Vicki Seyfert-Margolis; Kasia Bourcier; Jeffrey A Bluestone
Journal:  Clin Immunol       Date:  2009-05-14       Impact factor: 3.969

10.  In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants.

Authors:  K J Parlevliet; I J ten Berge; S L Yong; J Surachno; J M Wilmink; P T Schellekens
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.